StockData
Lexeo Therapeutics, Inc. logo

Lexeo Therapeutics, Inc. (LXEO) stock

LXEONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$2.95+0.10 (+3.33%)

Close on Nov 18, 2026Market cap $242.04MP/E –Yield –

Lexeo Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Lexeo Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$95.12M. For fiscal 2025 it was -$109.26M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$109.26M–
FY2024Dec 31, 2024-$105.77M–
FY2023Dec 31, 2023-$68.51M–
FY2022Dec 31, 2022-$60.51M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$28.02M–
Q1 FY2026Mar 31, 2026-$22.33M–
Q4 FY2025Dec 31, 2025-$23.12M–
Q3 FY2025Sep 30, 2025-$21.65M–
Q2 FY2025Jun 30, 2025-$30.69M–
Q1 FY2025Mar 31, 2025-$33.81M–
Q4 FY2024Dec 31, 2024-$27.38M–
Q3 FY2024Sep 30, 2024-$31.54M–
Q2 FY2024Jun 30, 2024-$23.55M–
Q1 FY2024Mar 31, 2024-$23.29M–
Q4 FY2023Dec 31, 2023-$14.97M–
Q3 FY2023Sep 30, 2023-$20.27M–
Q2 FY2023Jun 30, 2023-$13.98M–
Q1 FY2023Mar 31, 2023-$19.29M–
Q4 FY2022Dec 31, 2022-$15.20M–
Q3 FY2022Sep 30, 2022-$17.48M–

More Lexeo Therapeutics figures

See a number that looks wrong?